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Abstract (237 words) 
Background  In England, population mammographic screening has been offered to women for over 
20 years. Overall decrease in breast cancer mortality rates and improvements in cancer awareness 
and organisation of medical care over this period call for a more current evaluation of the mediators 
behind the better prognosis of screening-exposed breast cancers. 
Methods  A case-control study was conducted within the English National Breast Screening 
Programme. Women who died from primary breast cancer in 2008-09 were matched (by year of 
birth, screening invitation and area) to controls that received a diagnosis of invasive breast cancer at 
the time of the case diagnosis but survived the case death.  Data were analysed by unconditional 
logistic regression with adjustment for matching factors. 
Results  The unadjusted odds ratio (OR) for dying from breast cancer associated with ever having 
attended breast screening was 0.44 (95%CI 0.33-0.58). After adjustment for lead time, 
overdiagnosis, and self-selection, the OR increased to 0.69 (95%CI 0.50-0.94). Adjusting for tumour 
size, lymph node status, stage, grade, histopathology and laterality accounted for all the screening 
effect (OR=1.00, 95%CI 0.71-1.40). Further adjustment for treatment factors only had a minimal 
impact on the OR (OR=1.02, 95%CI 0.72-1.45). 
Conclusions  Our results suggest that earlier diagnosis, as reflected by tumour characteristics, 
remains the major mediator of the improvement in breast cancer survival due to participation in 
mammographic screening. 
Impact  Mammographic screening continues to prevent breast cancer deaths in the epoch of 
adjuvant systemic therapy. 
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Introduction 
Since the late 1970s, UK breast cancer mortality rates have been rising in all age groups alongside 
incidence rates until around 1990 when mortality rates started falling, including for women outside 
the screening age range (1),(2). This steady decrease is believed to be the result of (1) the 
implementation and improvement of the national screening programme , and (2) improvements in 
cancer staging and treatment including the use of adjuvant systemic therapies (3),(4),(5),(6). In 
addition, the inception of a screening service may have resulted in increased breast awareness 
(earlier response to self-detected breast symptoms) and coincided with better organisation of 
cancer care, including the implementation of multidisciplinary care in 1996 (7), possibly resulting in 
more effective treatment (8). The Cancer Intervention and Surveillance Modeling Network (CISNET) 
collaborators estimated that screening service delivery and advances in adjuvant treatment made 
similar large contributions to decreased mortality in the US (9). In Sweden, the majority of recent 
reductions in mortality in the screening age range were estimated to be due to screening (10). 
Screening is concerned with the detection of disease at an early detectable stage and can only 
reduce the rate of death when followed by effective treatment. The expectation is that treatment 
will be more effective if begun earlier in the disease process. If improvements in treatment are such 
that better survival is achieved regardless of disease stage at diagnosis, then identifying cancer in 
early stages becomes less critical, rendering breast screening less relevant. Screening may also lead 
to overdiagnosis, the detection and treatment of tumours which would not have come to clinical 
attention during the woman’s lifetime had screening not taken place (11). 
In England, population mammographic screening has been offered to women for over 20 years. It is 
therefore important to assess the role of screening on fatality from breast cancer in the context of 
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potential risks as well as benefits, and its current contribution to survival from breast cancer, 
independent of treatment. 
Here, we report on the results from a case-control study with an innovative design which allows us 
to compare cases who died from invasive primary breast cancer with controls who received a similar 
diagnosis but who survived the disease up to, and beyond the case’s death, with respect to 
attendance at breast screening prior to diagnosis. The impact of disease attributes and cancer 
treatment on the relative effect of attendance at breast screening was investigated. 
The purpose of this study was not to estimate the impact of screening on breast cancer mortality but 
to investigate sources of the difference in survival conferred by screening, with corrections for lead 
time, overdiagnosis and self-selection bias. The impact of screening on breast cancer mortality was 
assessed in a companion study (12). 
Material & Methods 
Study design 
We targeted women residing in the London region, who had been invited to participate in the NHS 
BSP from 1988 onwards, and who had not expressed dissent to their records being used for 
evaluation purposes. All women who died of primary breast cancer (as stated in part 1 of the death 
certificate) aged 47-89 between the 1st of January 2008 and the 31st of December 2009 and who had 
been first diagnosed with primary breast cancer (invasive) aged 47-89 and since 1990 were selected 
as cases. Cases identified as “Death Certificate Only” were excluded. Each case was matched to one 
control who was alive at the case date of death, was born within 4 months either side of the case 
date of birth, and was registered in the same cancer network as the case, at the case date of first 
diagnosis. The control had had a first diagnosis of primary breast cancer (invasive) within 6 months 
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prior to and including the case date of first diagnosis.  All cases and controls had been invited to take 
part in the NHS BSP at least once prior the date of their first diagnosis. 
Power calculation 
The odds ratio (OR) for breast cancer death associated with ever attending breast screening was 
postulated  to be equal to (or less than) the estimated 0.65 based on matched comparisons of breast 
cancer deaths with general population controls (13). With one control per case, 650 fatal cancers 
would provide 80% power to detect such an effect size at the 5% significance level using a 2-sided 
test (14). 
Data collection 
Tumour characteristics and treatment data were extracted from the National Cancer Data 
Repository (NCDR) by the National Cancer Intelligence Network (NCIN) London. Area-based 
deprivation quintiles based on the 2010 Income Domain of the English Indices of Multiple 
Deprivation (IMD) were also obtained (15). 
Screening history data were traced on the National Health Applications and Infrastructure Services 
(NHAIS) system of the HSCIC database. Only breast screens with invitation dates which occurred 
after the 1st of January 1988, within age range 47-73 at invitation and prior to and including date of 
first diagnosis were included in the analysis. For cervical screening (used in adjustment for self-
selection bias - see below), only screen dates which occurred after the 1st of January 1998, within 
age range 20-70 at screen and prior to and including date of first diagnosis were included in the 
analysis (cervical screening invitation data are not available on the NHAIS system). 
Statistical methods 
Regression modelling & adjustment for mediators of screening effect 
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Unusually, for a matched case-control study, the primary analysis had to be by unconditional logistic 
regression, with broad adjustment for the matching factors (cancer network registration and age at 
first diagnosis, and year of first diagnosis), as the correction for overdiagnosis (see below) entailed 
removal of large numbers of controls which would have lost the case information in a conditional 
analysis. After adjustment for overdiagnosis/lead time and self-selection bias, we adjusted for 
tumour characteristics (histopathological size, lymph node status, tumour stage as classified by the 
registry and dichotomized to localised (1) or extending beyond the organ (2-4), histological grade 
(Bloom-Scarff-Richardson (BRS)), histological type, and laterality), and for treatment - whether a 
woman received surgery (mastectomy or Breast Conservative Surgery (BCS)), radiotherapy, 
chemotherapy and/or endocrine therapy within 6 months of first diagnosis. 
Unknown tumour characteristics and treatment data were treated as separate categories. A 
sensitivity analysis was performed where relative effects of chemotherapy, radiotherapy and 
endocrine therapy compared to no treatment, from randomized trials, were included as offsets in 
the regression, based on data from the Early Breast Cancer Trialists’ Collaborative Group (16). For 
each treatment (except surgery), offsets were set to 1 if the treatment was not received and to the 
relevant ratio if treatment was received, i.e. 0.79 (95%CI 0.72-0.85) for polychemotherapy 
(anthracycline-based regimen) (17); 0.83 (95%CI 0.73–0.95), 0.79 (95%CI 0.65–0.95) and 0.82 (95%CI 
0.75–0.90) for radiotherapy of node-negative, node-positive, and node status unknown cancers 
respectively (18); and 0.76 (95%CI 0.70-0.82) for endocrine therapy (19). 
Collinearity between treatment and tumour characteristics was assessed using the inflation 
observed in the estimated standard errors of the regression coefficients and was judged to be 
negligible (20). 
Lead time, overdiagnosis & length bias 
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Lead-time, the amount of time by which the date of diagnosis has been advanced by screening as 
opposed to symptomatic detection, increases the apparent follow-up time of screen-detected 
cancers (defined in this study as cancers diagnosed in women having had their last breast screen 
within 90 of first diagnosis). This confers a survival bias in favour of screening. 
The individual lead time (ݐ) for the preclinical but screen-detectable phase was estimated for each 
screen-detected cancer assuming an exponential distribution with mean 1/ߣ , where for the rate of 
transition to symptomatic disease (λ), we used 0.25 (mean sojourn time = 4 years) as estimated by 
Tabar and coll. (21). 
For a screen-detected breast cancer patient who did not die of breast cancer (i.e. screen-detected 
controls), we sampled an unconditional random variable from the exponential distribution: 
ݐ =  − log (1 − ܷ݂݊݅݋ݎ݉ሾ0,1ሿ) ߣ⁄  . 
Overdiagnosis corresponds to the detection (and associated treatment) of tumours, which would not 
have come to clinical attention during the woman’s lifetime had screening not taken place. In our 
study design, the potential for overdiagnosis only applies to controls as by definition, cases were 
diagnosed with progressive (fatal) disease, and may confer a bias in favour of screening.  
Overdiagnosis can therefore be seen as an extreme form of lead-time bias among screen-detected 
cancers, in which the lead time exceeds the future life time. In our analysis, we adjusted for 
overdiagnosis by excluding control women with estimated lead time extending beyond the case’s 
date of death, and consequently we had to perform adjusted unconditional logistic regression 
analyses to avoid losing the corresponding case information. This is a highly conservative correction 
for overdiagnosis, since a control’s lead time exceeding the corresponding case’s time to death does 
not necessarily imply that the latter would exceed that control’s time to death. 
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Self-selection 
Self-selection, the voluntary compliance with the invitation to screening may bias the estimates of 
the effect of screening as factors related to both the decision to attend screening and the underlying 
risk of getting and/or dying from breast cancer may confound the relationship between exposure to 
screening and disease outcome. 
The OR (߰) was  corrected for self-selection bias using the formula derived by Duffy et al. (22) where 
a correction factor ‘ܦ௥’ is defined as the relative risk of breast cancer death for non-attenders 
compared to the not invited.  
߰ᇱ = ߰. ݌. ܦ௥  (1 − (1 − ݌). ܦ௥⁄ )  
where ݌ is the proportion of control women who attend the screening invitation. ‘ܦ௥’ was estimated 
using the relative risk of breast cancer death in non-attenders to the cervical screening programme 
compared to the general population, adjusted for confounding of cervical screening attendance with 
breast screening attendance (see details in (23)). 
For ever attendance at breast screening, a sensitivity analysis was also performed where the OR was 
calculated for women attenders among the invited compared to women who would have attended if 
invited (see details in (23)). 
For analyses of time since last screen, the logistic regression was adjusted for deprivation, thought 
to be the major driver of self-selection bias in this context, and contemporary attendance at cervical 
screening prior to diagnosis using a 3-category variable in order to partially account for self-
selection: “Never screened”, “Formerly screened (> 60 months)” and “Currently screened (0 - 60 
months)”. 
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All statistical analyses were performed using the statistical software R version 2.13.0 (The R 
Foundation for Statistical Computing, http://www.r-project.org/foundation). 
Ethics 
This study is part of a protocol for the on-going evaluation of the English NHS BSP and has received 
all relevant approvals (details published elsewhere (24)). 
Results 
Data description 
1,493 breast cancer deaths were registered in London during 2008-09, and 1,192 of these were able 
to be matched to diseased controls and traced for screening history (Figure 1). Among these 1,192 
pairs, 22 were excluded due to a first diagnosis being an in situ disease (8 controls & 14 cases) and 
491 for not having been invited to the NHS BSP at least once prior to their first diagnosis (391 
controls & 417 cases), leaving 679 pairs in the dataset for the main analysis.  
Over 80% of women in our dataset selected were diagnosed from the year 2000 onwards (Table 1a). 
As per study design, cases and controls had the same median age at diagnosis (63 years old). Median 
age at death for the cases was 68 years old. 
Median age at first NHS BSP invitation was 52 years for both groups. Among compliers with breast 
screening, median age at first breast screen was very similar (53 years old), while the proportion of 
women who never attended screening was larger for cases than for controls (26.4% versus 13.7%), 
and was mirrored by a larger proportion of control women having attended screening more than 
once (61.9% versus 48.2%). In addition, time since last breast screen was over a year longer for the 
case population (1.2 versus 2.4 years) and the number of screen-detected cancers, defined as 
cancers diagnosed in women having had their last breast screen within 90 of first diagnosis, was 
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higher among controls than cases (37.1% versus 18.7%). Controls also attended their last or 
penultimate invitation in larger proportion (41.7% versus 33.3%, and 57.7% versus 47.3%, 
respectively, Table 1b). 
Impact of lead time, overdiagnosis and self-selection on the relative effect of exposure to breast 
screening 
When assessing the effect of having attended at least one breast screen prior to first diagnosis on 
case fatality from breast cancer, the conditional OR (cOR) and the unconditional OR (uOR) adjusted 
for matching factors were found to be very similar (cOR=0.42, 95%CI 0.30-0.56 and uOR=0.44, 95%CI 
0.33-0.58, respectively, Table 2). 
To account for overdiagnosis, the unconditional analysis was repeated after excluding screen-
detected controls with an estimated lead time extending beyond the date of death of their matched 
case (uOR=0.55, 95%CI 0.42-0.73, Table 2). 
The treatment profile of early stage (localised) screen-detected cancers among women diagnosed 
age 47-74, potentially associated with overdiagnosis/overtreatment, was found to be less aggressive 
than that of symptomatic cancers (Table 3): only 9% of screen-detected women received 
chemotherapy and (an additional) 12% had mastectomy. The corresponding figures for symptomatic 
cancers were 19% and 29%.  
Adjustment for deprivation had minimal impact on the relative effect of screening (uOR=0.56, 95%CI 
0.42-0.75). Regular attendance at cervical screening (as measured by attendance in the last 5 years 
compared to never screened), but not deprivation, was an inverse predictor of primary breast cancer 
outcome (uOR= 0.75, 95%CI 0.54-1.03, p=0.08). Adjusting for self-selection using a ‘ܦ௥’ estimated 
based on attendance at the cervical screening programme (ܦ௥=1.19, 95%CI 1.05-1.36, see details in 
(23)) increased the uOR to 0.69 (95% CI 0.50-0.94, Table 2). This estimate was very close to a 
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sensitivity estimate of the OR calculated using women attenders among the invited compared to 
women who would have attended if invited (0.71, 95%CI 0.52-0.97, see details in (23)). 
After excluding screen-detected cancers from the analysis, the unconditional OR was 0.60 (95%CI 
0.45-0.81); it increased to 0.81 (95%CI 0.59-1.12) after adjustment for deprivation and correction for 
self-selection which was found to be larger in this subgroup of screen-exposed symptomatic women 
compared to the never screened (ܦ௥=1.24, 95%CI 1.09-1.40, , see details in (23) and Table 2). 
The risk of fatality reversed slightly with time since last screen compared to no screening with a 
conditional OR of 0.68 (95%CI 0.47-0.98) for last attendance over 5 years prior to first diagnosis, 
down to 0.59 (95%CI 0.39-0.89) for time since last screen of between 3 months and 2 years (Table 4). 
The better prognosis observed for screen-detected cancers in this analysis is strongly affected by 
overdiagnosis, lead time and length biases, so no inferences are made from this estimate. 
Impact of disease attributes and cancer treatment on the relative effect of exposure to breast 
screening 
Tumour size, tumour stage and surgery were the most single influential factors on the OR of the 
effect of screening: from uOR=0.56 (95%CI 0.42-0.75) after adjustment for overdiagnosis/lead time 
and deprivation, to uOR=0.70 (95%CI 0.52-0.94), uOR=0.63 (95%CI 0.47-0.85), and uOR=0.68 (95%CI 
0.51-0.92), respectively. 
The model was adjusted for tumour characteristics at diagnosis, which included tumour size, lymph 
node status, extension beyond organ (registry-based measure of stage), histological grade, 
histological type, and laterality (Table 1c): the unconditional OR of attending at least one routine 
breast screen prior to first diagnosis increased from 0.69 (95% CI 0.50-0.94, after correction for self-
selection) to 1.00 (95%CI 0.71-1.40, Table 2), the tumour characteristics accounting entirely for the 
effect of screening. 
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Additional adjustment for treatment factors (surgery, radiotherapy, chemotherapy and endocrine 
therapy) had little impact on the OR (uOR=1.02, 95%CI 0.72-1.45). Using treatment effect estimates 
based on RCT data resulted in similar adjustment in the OR (uOR=1.04, 95%CI 0.73-1.49, Table 2). 
Similar observations were made regarding the mediation, through disease attributes and treatment, 
of the effect of ever attending breast screening for symptomatic cancers (Table 2), and in terms of 
time since last screen in all cancers (Table 4). 
Discussion 
We estimated the impact of breast screening attendance on breast cancer fatality and investigated 
the current mediators of that effect. The study was carried out using an innovative case-control 
design in an urban region (London) with relatively low rates of participation in screening. 
Attendance in the NHS BSP reduced fatality risk was by 45% after accounting for overdiagnosis and 
lead time in screen-detected cancers, and by 34% after additionally accounting for deprivation and 
self-selection. We found the major intermediaries between screening and survival to be the 
traditional tumour characteristics, in particular smaller size and extension beyond the breast, rather 
than differential treatment, in agreement with previously findings (25),(26),(27),(28),(29). We also 
observed increased fatality in left-sided or bilateral tumours.  Reduction in size and likelihood of 
spread beyond the organ are considered a necessary effect of a screening programme (5). Our 
results are in agreement with recent reports comparing parallel cohorts in Denmark and Norway, 
which observed a residual effect of screening after introduction of multidisciplinary medical care in 
breast cancer management (30),(31). 
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After adjusting for these disease attributes, and for treatment (in addition to overdiagnosis and lead 
time), most of the screening effect (screen and interval detection) was accounted for, leaving little 
scope for other factors to explain the better prognosis of screening. 
A beneficial effect of attendance at breast screening was also observed among screen-exposed 
women diagnosed with symptomatic cancers (40% for interval detection) compared to never 
screened, although this effect was no longer significant at the 5% level after correcting for self-
selection (19% reduction). The residual benefit of screening was also explained by the characteristics 
of their tumour as previously noted by Day et al. (32). Interval tumours have previously been found 
to be smaller (and more likely to be estrogen receptor-positive) and associated with better survival 
than tumours in the unscreened population (33),(34),(35). We and others have noted that the 
survival benefit in interval cancers diminishes with time since last screen (36),(37), suggesting that 
the effect of attendance at breast screening is not entirely due to self-selection, while others have 
not (36). 
Women who participated in the screening programme but whose cancer was not screen-detected 
may have developed increased self-awareness as a consequence of the information provided during 
the screening process: Tyndel et al. (38), have reported that women who had a recall had become 
more aware of their risk of developing breast cancer. 
Deprivation is believed to be the main confounding factor between the decision to attend screening 
and cancer survival: in England, deprivation is associated with lower attendance at breast screening 
after adjustment for other socio-demographic factors, such as urbanisation and the percentage of 
ethnic minorities (39), and cancer survival is lowest in the most deprived areas (40). Deprivation 
adjustment had no impact on the OR pertaining to attendance at breast screening in spite of having 
been shown to impact both attendance at breast screening and survival from breast cancer (41), 
possibly because cases and controls were matched for diagnosis in the same cancer network, 
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imposing a degree of residential proximity. A similar observation was made for the case-control 
nested within the UK Age Trial which assessed the effect of the NHS BSP in a cohort of women age 
40-49 (42). 
To address self-selection , we chose to use a new approach based on contemporary attendance at 
cervical screening  to estimate the underlying risk of breast cancer death in the different screening 
groups compared (23). Our results suggest that self-selection bias among this group of women at 
higher risk of breast cancer is larger than among the general population (12).  
Screening is likely to pick up cancers with best and worst prognosis. The fact that the effect of 
screening is minimal once the regression has been adjusted for tumour characteristics suggests that 
screening downstage tumours. Further investigation into the impact of tumour characteristics and 
treatment was limited by the absence of information on receptor status and other biological 
attributes (43), or type of endocrine therapy. Recent studies have questioned the relevance of 
tumour staging in treatment decisions, while histological and molecular characterisation of tumours 
and surrounding tissues have been shown to predict clinical outcomes (44),(45),(46),(47). 
There has been limited scope for the clear distinction of fast- versus slow-growing or steady-state 
tumours (48),(49), and correspondingly, it has been considered necessary to intervene once a 
tumour has been diagnosed. Both invasive and in situ lesions have been found to have the potential 
to recur and metastasize, or to remain symptomless (indolent disease) (50),(51). An estimated 7% 
(range 3-15%) of 40–80 year-old women of various ethnical backgrounds are found to have 
undiagnosed, mainly in situ, breast cancer at autopsy (reviewed in (52)). Given the upper limit 
provided by the autopsy results, and the limitations of mammographic detection - an average of 
1.16 cm threshold for women aged 50 to 69 (53) -, we believe that our approach which excluded 
approximately 15% of screen-detected controls accounted adequately for overdiagnosis & lead time. 
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In addition, our data suggest that the treatment associated with potential overdiagnosis, i.e. among 
screen-detected women diagnosed with early stage cancers after attending an invitation, tend to be 
less aggressive compared to the treatment received by early stage cancers detected 
symptomatically, i.e. they rarely - if ever - includes mastectomy or chemotherapy. 
In 2013, the UK Independent Review panel of mammographic screening felt that the benefits of 
screening and those of improved treatments could reasonably be considered independent (6). If the 
recent improvements in treatment indeed rendered early detection redundant or less effective, we 
might have expected to see attenuation of the screening effect on fatality by adjustment for 
treatment factors. This was not the case. We found that most of the improved fatality associated 
with screening exposure was due to tumour characteristics, in common with earlier studies 
(25),(26),(27),(28),(29). 
It is worth observing that effects of treatment in a non-randomised setting are themselves subject to 
selection bias, in that those given the most aggressive treatments tend to be those cases at most risk 
of poor outcome (54),(55). This was the case in this study with chemotherapy (data not shown). 
Accordingly, additionally to conventional adjustment, we also adjusted for the effects of therapies as 
found in meta-analyses of the randomised trials (16). The results were the same, in that the major 
mediating factors for the lower fatality of screening-exposed cases were the tumour characteristics 
rather than treatment.  
In this study, over 80% of the women included received cancer treatment spanning over the last 
decade (2000-2009). In addition, the study design was such that epoch of diagnosis was confounded 
with the survival of the cases. It was therefore not possible to assess any change over time in the 
relative contribution of treatment o the screening effect, and hence the extents to which time 
trends in mortality are due to screening or treatment? 
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Extension of this case-control study design to other regions of England will provide insight into 
regional self-selection factors. In addition, one of the companion case-control studies, designed 
alongside this one, will allow us to quantify the rate of overdiagnosis within the current English 
Breast Screening Programme. In the meantime, our results suggest a substantial reduction in case 
fatality in screening-exposed breast cancer cases. This is largely attributable to more favourable 
tumour characteristics, consistent with the effect of early detection. 
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Tables 
Table 1  Patient demographics, screening history, tumour characteristics and treatment by 
case-control status 
Table 1a Patient demographics 
 Controls Cases 
Breast cancer diagnosis & death   
Year of diagnosis (Count, %)    
1991-1994 13 (1.9) 13 (1.9) 
1995-1999 69 (10.2) 69 (10.2) 
2000-2004 207 (30.5) 196 (28.9) 
2005-2009 390 (57.4) 401 (59.1) 
Age at diagnosis (Count, %)   
47 - 55 103 (15.2) 103 (15.2) 
55 – 59 158 (23.3) 155 22.8) 
60 – 64 128 (18.9) 128 (18.9) 
65 - 69 109 (16.1) 110 (16.2) 
70 – 74 112 (16.5) 109 (16.1) 
75 - 89 69 (10.2) 74 10.9) 
Median age at diagnosis in years (range) 63.0 (49.9 – 82.5) 63.2 (50.2 – 82.6) 
Age category at death (Count, %)  
47 - 55 _ 24 (3.5) 
55 – 59 _ 95 (14.0) 
60 – 64 _ 144 (21.2) 
65 - 69 _ 127 (18.7) 
70 – 74 _ 135 (19.9) 
75 - 89 _ 154 (22.7) 
Median age at death in years (range)  NA(a) 68.2 (51.6 – 84.2) 
(a) 102 out of 679 controls (15%) died between the date of death of their matched case and the censor date of 28th 
February 2013, among whom 58 died of breast cancer (8.5% of total). 
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Table 1b Patient screening history 
 Controls Cases 
Breast screening history   
Number of screening invitations (Count, %)   
1 136 (20.0) 164 (24.2) 
2 155 (22.8) 157 (23.1) 
 2+ 388 (57.2) 358 (52.7) 
Median number of screening invitations (range)  3.0 (1 – 8) 3.0 (1 - 8) 
Attendance at first invitation   
Did not attend 93 (13.7) 179 (26.4) 
Attended 586 (86.3) 500 (73.6) 
Attendance at penultimate invitation  
Did not attend 287 (42.3) 358 (52.7) 
Attended 392 (57.7) 321 (47.3) 
Attendance at last invitation   
Did not attend 396 (58.3) 453 (67.7) 
Attended 283 (41.7) 226 (33.3) 
Median age at first screening invitation in years (range) 52.4 (47.3 – 73.1) 52.4 (47.5 – 70.3) 
Number of screens (Count, %)   
                             0 (Never screened) 93 (13.7) 179 (26.4) 
1 167 (24.6) 173 (25.5) 
 1+ 419 (61.7) 327 (48.1) 
Median number of screens (range)  2.0 (0 – 7) 1.0 (0 – 8) 
Time since last screen in months (Count, %)   
Never screened 93 (13.7) 179 (26.4) 
>72 months 130 (19.1) 147 (21.6) 
48-72 months 40 (5.9) 38 (5.6) 
24-48 months 82 (12.1) 97 (14.3) 
3-24 months 82 (12.1) 91 (13.4) 
≤ 3 months 252 (37.1) 127 (18.7) 
Median time since last screen in years (range)
– among compliers 
1.2
(0 days – 18.2 years) 
2.4 
(0 days – 19.2 years) 
Median age at first screen in years (range) 
– among compliers 
53.5 (47.3 – 73.5) 53.8 (47.7 – 70.3) 
Median age at last screen in years (range) 
– among compliers 
61.3 (49.9 – 73.7) 61.1 (49.1 – 72.6) 
Self-selection variables   
Deprivation quintile(b) (Count, %)   
Least deprived Q1 99 (14.6) 93 (13.7) 
Q2 107 (15.8) 102 (15.1) 
Q3 132 (19.5) 122 (18.0) 
Q4 161 (23.8) 172 (25.4) 
Most deprived Q5 177 (26.2) 188 (27.8) 
Attendance at cervical screening (Count, %)   
Never screened 116 (17.1) 149 (21.9) 
Formerly screened (>60 months) 214 (31.5) 229 (33.7) 
Currently screened (0-60months) 349 (51.4) 301 (44.3) 
(b) Index of Multiple Deprivation (IMD) Income domain quintile 
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Table 1c Patient treatment and tumour characteristics 
 Controls Cases 
Treatment   
Any treatment   
No / NK 65 (9.6) 139 (20.5) 
Yes 614 (90.4) 540 (79.5) 
Surgery  
No / NK 124 (18.3) 300 (44.2) 
BCS 363 (53.5) 185 (27.2) 
Mastectomy 192 (28.3) 194 (28.6) 
Radiotherapy  
No / NK 398 (58.6) 502 (73.9) 
Yes 281 (41.4) 177 (26.1) 
Chemotherapy   
No / NK 533 (78.5) 399 (58.8) 
Yes 146 (21.5) 280 (41.2) 
Endocrine therapy  
No / NK 409 (60.2) 501 (73.8) 
Yes 270 (39.8) 178 (26.2) 
Tumour characteristic   
Size (mm)    
≤20 265 (39.0) 104 (15.3) 
>20 206 (30.3) 217 (32.0) 
NK 208 (30.6) 358 (52.7) 
Number of affected regional lymph nodes   
0 423 (62.3) 270 (39.8) 
1-3 107 (15.8) 115 (16.9) 
4+ 57 (8.4) 126 (18.6) 
NK 92 (13.5) 168 (24.7) 
Stage   
Early/Localised to breast 282 (41.5) 113 (16.6) 
Advanced/Spread beyond breast 168 (24.7) 375 (55.2) 
NK 229 (33.7) 191 (28.1) 
Histological grade (BRS)  
1 129 (19.0) 31 (4.6) 
2 252 (37.1) 195 (28.7) 
3 158 (23.3) 232 (34.2) 
NK 140 (20.6) 221 (32.5) 
Histological type  
Ductal 530 (78.1) 553 (81.4) 
Lobular 97 (14.3) 96 (14.1) 
Other 52 (7.7) 30 (4.4) 
Tumour laterality  
Right 329 (48.5) 277 (40.8) 
Left (or bilateral) 338 (49.8) 352 (51.8) 
NK 12 (1.8) 50 (7.4) 
NK: Not Known; BCS, Breast Conservation Surgery; BRS: Bloom-Scarff-Richardson 
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Table 2  Impact of disease attributes and cancer treatment on the relative effect of 
exposure to breast screening according to ever attendance and attendance at last invitation. 
Treatment variables included surgery, radiotherapy, chemotherapy and endocrine therapy; tumour characteristics included 
size, lymph node status, stage, histological grade, histological type, and laterality. 
 
Exposure to screening 
 
 
Correction/adjustment OR 
(95% CI, p-value) 
Never screened  1.00 (-) 
Screen-exposed 
(all) 
None (conditional analysis, N pairs = 679) 0.42 (0.31 - 0.56, <0.001) 
 Unconditional analyses
 None (matching factors only) 0.44 (0.33 – 0.58, <0.001)
 OD/LT(a) 0.55 (0.42 – 0.73, <0.001)
 OD/LT + Deprivation(b) 0.56 (0.42 - 0.75, 0.001)
 OD/LT + Deprivation + SS(c)   D୰ = 1.19 (1.05 – 1.36) 0.69 (0.50 – 0.94, 0.02)
 OD/LT + Deprivation + Tumour characteristics + SS 1.00 (0.71 – 1.40, 0.9)
 OD/LT + Deprivation + Tumour characteristics + Treatment + SS 1.02 (0.72 - 1.45, 0.9)
 OD/LT + Deprivation + Tumour characteristics + RCT treatments as offsets + SS 1.04 (0.73 – 1.49, 0.8) 
Never screened  1.00 (-)
Screen-exposed, 
symptomatic only 
None (conditional analysis, N pairs = 362) 0.56 (0.38 – 0.80, 0.002)
 Unconditional analyses  
 None (matching factors only) 0.60 (0.45 – 0.81, <0.001) 
 OD/LT(a) NA 
 Deprivation(b) 0.61 (0.46 – 0.83, 0.001) 
 Deprivation + SS(c)   D୰ = 1.24 (1.09 – 1.40) 0.81 (0.59 – 1.12, 0.2) 
 Deprivation + Tumour characteristics + SS 1.01 (0.71 – 1.44, 0.9) 
 Deprivation + Tumour characteristics + Treatment + SS 1.01 (0.70 – 1.45, 0.9) 
 Deprivation + Tumour characteristics + RCT treatments as offsets + SS 1.06 (0.74 – 1.52, 0.7)
(a) Exclusion of screen-detected controls with lead time extending beyond the matched case date of death. 
(b) Self-selection adjustment using deprivation quintile (see categorization in Table 1b). 
(c) Self-selection correction of OR using data on attendance at the cervical screening programme (described in (23)) 
NA: Not Applicable; OD/LT: overdiagnosis & lead time adjustment; SS: self-selection 
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Table 3  Treatment profile of early stage (localised to breast) cancers received by control 
women diagnosed with screened-detected versus symptomatic cancers (age at diagnosis 47-74) 
Surgery 
 
Chemotherapy Other therapy Controls (count, %) 
   Screen-detected
N = 113 
All symptomatic(a)
N = 132 
     
No No None 1  (0.9) 4  (3.0) 
  Endocrine 1  (0.9) 4  (3.0) 
  Radio ±Endocrine 3  (2.7) 2  (1.5) 
    
BCS No None ±Endocrine 23  (20.4) 18  (13.6) 
  Radio ±Endocrine 61  (54.0) 42  (31.8) 
     
Mastectomy No None ±Endocrine 12  (10.6) 31  (23.5)
  Radio ±Endocrine 2  (1.8) 7  (5.3) 
     
Any surgery Yes Any 10  (8.8) 24  (18.2) 
   
(a) Screen-exposed and never screened symptomatic cancers. 
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Table 4  Impact of disease attributes and cancer treatment on the relative effect of exposure to breast screening according to time since last 
breast screen 
Treatment variables included surgery, radiotherapy, chemotherapy and endocrine therapy; tumour characteristics included size, lymph node status, stage, histological grade, histological type, 
and laterality. 
Time since last 
breast screen 
 
Adjustment  OR (95% CI, p-value) 
Never screened  _  1.00 (-) 
Screened 3-36 months Deprivation + Attendance at cervical screening 0.60 (0.42 – 0.85, 0.004) 
Screened >60 months Deprivation + Attendance at cervical screening(a) 0.68 (0.47 – 0.98, 0.04)
Screened 36-60 months  Deprivation + Attendance at cervical screening 0.63 (0.37 – 1.05, 0.07)
Screened 24-36 months  Deprivation + Attendance at cervical screening 0.61 (0.39 – 0.93, 0.02)
Screened 3-24 months  Deprivation + Attendance at cervical screening 0.59 (0.39 – 0.89, 0.01)
Screened ≤3 months(a)  Deprivation + Attendance at cervical screening 0.26 (0.18 – 0.37, <0.001)
Screened 3-36 months Deprivation + Attendance at cervical screening + Tumour characteristics 0.73 (0.50 – 1.08, 0.1) 
Screened >60 months Deprivation + Attendance at cervical screening + Tumour characteristics 0.82 (0.55 – 1.25, 0.4)
Screened 36-60 months  Deprivation + Attendance at cervical screening + Tumour characteristics 0.85 (0.48 – 1.50, 0.6)
Screened 24-36 months  Deprivation + Attendance at cervical screening + Tumour characteristics 0.75 (0.47 – 1.21, 0.2)
Screened 3-24 months  Deprivation + Attendance at cervical screening + Tumour characteristics 0.72 (0.46 – 1.13, 0.2) 
Screened ≤3 months  Deprivation + Attendance at cervical screening + Tumour characteristics 0.59 (0.39 – 0.88, 0.01) 
Screened 3-36 months Deprivation + Attendance at cervical screening + Tumour characteristics + Treatment 0.74 (0.50 – 1.10, 0.1) 
Screened >60 months Deprivation + Attendance at cervical screening + Tumour characteristics + Treatment 0.81 (0.53 – 1.24, 0.3)
Screened 36-60 months  Deprivation + Attendance at cervical screening + Tumour characteristics + Treatment 0.90 (0.50 – 1.24, 0.7) 
Screened 24-36 months  Deprivation + Attendance at cervical screening + Tumour characteristics + Treatment 0.76 (0.47 – 1.24, 0.3) 
Screened 3-24 months  Deprivation + Attendance at cervical screening + Tumour characteristics + Treatment 0.73 (0.46 – 1.16, 0.2) 
Screened ≤3 months  Deprivation + Attendance at cervical screening + Tumour characteristics + Treatment 0.64 (0.42 – 0.97, 0.03) 
(a) Self-selection adjustment using deprivation quintile and attendance at cervical screening. See categorization in Table 1b. 
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